Literature DB >> 9402657

Long-term cytokine production from engineered primary human stromal cells influences human hematopoiesis in an in vivo xenograft model.

M A Dao1, K A Pepper, J A Nolta.   

Abstract

Human hematopoiesis can be supported in beige/nude/ XID (bnx) mice by coinjection of human bone marrow stromal cells engineered to secrete human interleukin 3 (HuIL-3). The major limitation is a total absence of human B cell development in the mice, which could be due to supraphysiological levels of HuIL-3 in the circulation. In an effort to obtain human B lymphoid, as well as T lymphoid and myeloid cell development in the mice, CD34+ cells were coinjected with human marrow stromal cells engineered to secrete human IL-2, IL-7, stem cell factor or FLT3 ligand, +/- IL-3. No single factor other than IL-3 supported sustained human hematopoiesis in the mice, although cytokines were expressed for four to six months post-transplantation. Production of both HuIL-3 and IL-7 in the mice supported extrathymic development of human T lymphocytes, but no B cells, myeloid cells, or clonogenic progenitors were detected. Human B cells were not produced from CD34+ cells in the bnx mice under any condition tested. Another limitation to the bnx/Hu system is a lack of maturation of human red blood cells, although BFU-E are maintained. Stromal cells secreting human erythropoietin and IL-3 were cotransplanted into mice with HuCD34+ cells and an increase in hematocrit from 40%-45% to 80%-85% resulted, with production of human and murine red blood cells. Unfortunately, all mice (n = 9) suffered strokes, displayed paralysis and died within three weeks. The bnx/Hu cotransplantation model provides an interesting system in which to study human hematopoietic cell differentiation under the influence of various cytokines.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9402657      PMCID: PMC3045697          DOI: 10.1002/stem.150443

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  22 in total

1.  Early arrest of B cell development in nude, X-linked immune-deficient mice.

Authors:  D Karagogeos; N Rosenberg; H H Wortis
Journal:  Eur J Immunol       Date:  1986-09       Impact factor: 5.532

2.  Absence of thymus in a mouse mutant.

Authors:  E M Pantelouris
Journal:  Nature       Date:  1968-01-27       Impact factor: 49.962

Review 3.  Control points in early T-cell development.

Authors:  D I Godfrey; A Zlotnik
Journal:  Immunol Today       Date:  1993-11

4.  Modulation of early B lymphopoiesis by interleukin-3.

Authors:  T C Ball; F Hirayama; M Ogawa
Journal:  Exp Hematol       Date:  1996-08       Impact factor: 3.084

5.  Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized CD34+ cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes.

Authors:  G Bauer; P Valdez; K Kearns; I Bahner; S F Wen; J A Zaia; D B Kohn
Journal:  Blood       Date:  1997-04-01       Impact factor: 22.113

6.  Improved engraftment of human spleen cells in NOD/LtSz-scid/scid mice as compared with C.B-17-scid/scid mice.

Authors:  D L Greiner; L D Shultz; J Yates; M C Appel; G Perdrizet; R M Hesselton; I Schweitzer; W G Beamer; K L Shultz; S C Pelsue
Journal:  Am J Pathol       Date:  1995-04       Impact factor: 4.307

7.  Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs.

Authors:  C Hannum; J Culpepper; D Campbell; T McClanahan; S Zurawski; J F Bazan; R Kastelein; S Hudak; J Wagner; J Mattson
Journal:  Nature       Date:  1994-04-14       Impact factor: 49.962

8.  Sustained human hematopoiesis in immunodeficient mice by cotransplantation of marrow stroma expressing human interleukin-3: analysis of gene transduction of long-lived progenitors.

Authors:  J A Nolta; M B Hanley; D B Kohn
Journal:  Blood       Date:  1994-05-15       Impact factor: 22.113

9.  Interleukin 3 or interleukin 1 abrogates the reconstituting ability of hematopoietic stem cells.

Authors:  Y Yonemura; H Ku; F Hirayama; L M Souza; M Ogawa
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

10.  Transduction of pluripotent human hematopoietic stem cells demonstrated by clonal analysis after engraftment in immune-deficient mice.

Authors:  J A Nolta; M A Dao; S Wells; E M Smogorzewska; D B Kohn
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

View more
  22 in total

Review 1.  Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors.

Authors:  Todd Meyerrose; Scott Olson; Suzanne Pontow; Stefanos Kalomoiris; Yunjoon Jung; Geralyn Annett; Gerhard Bauer; Jan A Nolta
Journal:  Adv Drug Deliv Rev       Date:  2010-10-13       Impact factor: 15.470

2.  Characterization and in vivo testing of mesenchymal stem cells derived from human embryonic stem cells.

Authors:  William Gruenloh; Amal Kambal; Claus Sondergaard; Jeannine McGee; Catherine Nacey; Stefanos Kalomoiris; Karen Pepper; Scott Olson; Fernando Fierro; Jan A Nolta
Journal:  Tissue Eng Part A       Date:  2011-03-04       Impact factor: 3.845

Review 3.  Wharton's Jelly Mesenchymal Stromal Cells as a Feeder Layer for the Ex Vivo Expansion of Hematopoietic Stem and Progenitor Cells: a Review.

Authors:  Melania Lo Iacono; Rita Anzalone; Giampiero La Rocca; Elena Baiamonte; Aurelio Maggio; Santina Acuto
Journal:  Stem Cell Rev Rep       Date:  2017-02       Impact factor: 5.739

Review 4.  Engineering humanized mice for improved hematopoietic reconstitution.

Authors:  Adam C Drake; Qingfeng Chen; Jianzhu Chen
Journal:  Cell Mol Immunol       Date:  2012-03-19       Impact factor: 11.530

5.  shRNA-mediated decreases in c-Met levels affect the differentiation potential of human mesenchymal stem cells and reduce their capacity for tissue repair.

Authors:  Ivana Rosová; Daniel Link; Jan A Nolta
Journal:  Tissue Eng Part A       Date:  2010-08       Impact factor: 3.845

6.  In vivo distribution of human adipose-derived mesenchymal stem cells in novel xenotransplantation models.

Authors:  Todd E Meyerrose; Daniel A De Ugarte; A Alex Hofling; Phillip E Herrbrich; Taylor D Cordonnier; Leonard D Shultz; J Chris Eagon; Louisa Wirthlin; Mark S Sands; Marc A Hedrick; Jan A Nolta
Journal:  Stem Cells       Date:  2006-09-07       Impact factor: 6.277

7.  Molecular mechanism of transforming growth factor beta-mediated cell-cycle modulation in primary human CD34(+) progenitors.

Authors:  Mo A Dao; Joseph Hwa; Jan A Nolta
Journal:  Blood       Date:  2002-01-15       Impact factor: 22.113

8.  A novel xenograft model to study the role of TSLP-induced CRLF2 signals in normal and malignant human B lymphopoiesis.

Authors:  Olivia L Francis; Terry-Ann M Milford; Shannalee R Martinez; Ineavely Baez; Jacqueline S Coats; Karina Mayagoitia; Katherine R Concepcion; Elizabeth Ginelli; Cornelia Beldiman; Abigail Benitez; Abby J Weldon; Keshav Arogyaswamy; Parveen Shiraz; Ross Fisher; Christopher L Morris; Xiao-Bing Zhang; Valeri Filippov; Ben Van Handel; Zheng Ge; Chunhua Song; Sinisa Dovat; Ruijun Jeanna Su; Kimberly J Payne
Journal:  Haematologica       Date:  2015-11-26       Impact factor: 9.941

9.  Isolation, characterization, and transplantation of bone marrow-derived cell components with hematopoietic stem cell niche properties.

Authors:  Naser Ahmadbeigi; Masoud Soleimani; Mohammad Vasei; Yousof Gheisari; Yousef Mortazavi; Kayhan Azadmanesh; Azadeh Omidkhoda; Ehsan Janzamin; Nance Beyer Nardi
Journal:  Stem Cells Dev       Date:  2013-09-14       Impact factor: 3.272

Review 10.  Contribution of human hematopoietic stem cells to liver repair.

Authors:  Ping Zhou; Louisa Wirthlin; Jeannine McGee; Geralyn Annett; Jan Nolta
Journal:  Semin Immunopathol       Date:  2009-06-17       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.